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P2X7 is a transmembrane receptor expressed in multiple cell types including neurons,
dendritic cells, macrophages, monocytes, B and T cells where it can drive a wide range of
physiological responses from pain transduction to immune response. Upon activation by
its main ligand, extracellular ATP, P2X7 can form a nonselective channel for cations to
enter the cell. Prolonged activation of P2X7, via high levels of extracellular ATP over an
extended time period can lead to the formation of a macropore, leading to depolarization
of the plasma membrane and ultimately to cell death. Thus, dependent on its activation
state, P2X7 can either drive cell survival and proliferation, or induce cell death. In cancer,
P2X7 has been shown to have a broad range of functions, including playing key roles in
the development and spread of tumor cells. It is therefore unsurprising that P2X7 has been
reported to be upregulated in several malignancies. Critically, ATP is present at high
extracellular concentrations in the tumor microenvironment (TME) compared to levels
observed in normal tissues. These high levels of ATP should present a survival challenge
for cancer cells, potentially leading to constitutive receptor activation, prolonged
macropore formation and ultimately to cell death. Therefore, to deliver the proven
advantages for P2X7 in driving tumor survival and metastatic potential, the P2X7
macropore must be tightly controlled while retaining other functions. Studies have
shown that commonly expressed P2X7 splice variants, distinct SNPs and post-
translational receptor modifications can impair the capacity of P2X7 to open the
macropore. These receptor modifications and potentially others may ultimately protect
cancer cells from the negative consequences associated with constitutive activation of
P2X7. Significantly, the effects of both P2X7 agonists and antagonists in preclinical tumor
models of cancer demonstrate the potential for agents modifying P2X7 function, to
provide innovative cancer therapies. This review summarizes recent advances in
understanding of the structure and functions of P2X7 and how these impact P2X7
roles in cancer progression. We also review potential therapeutic approaches directed
against P2X7.
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Extracellular ATP is a danger associated molecular pattern
(DAMP), which can act through the P2 receptor family
including ionotropic P2X ion channel receptors and the G
protein-coupled P2Y receptor family (Abbracchio and
Burnstock, 1994; Brake et al., 1994; Valera et al., 1994; North,
2002; Burnstock, 2014). The P2X receptor family is formed by
seven members able to assemble into homo- and hetero-trimers
at the cell membrane (North, 2002; Burnstock, 2006). P2X family
members are distinguished by their relative affinities to ATP,
within the nanomolar range for P2X1 and P2X3, the low
micromolar range for P2X2, P2X4, and P2X5 and the
hundreds of micromolar range for P2X7 and also their rate of
channel desensitization, milliseconds for P2X1 and P2X3,
seconds for P2X2, P2X4, and P2X5 and no observable
desensitization for P2X7, (Koshimizu et al., 1999; North and
Surprenant, 2000; North, 2002; Burnstock, 2006; Jarvis and
Khakh, 2009; Yan et al., 2010; Coddou et al., 2011).
P2X7 is characterized by its biphasic response to ATP
stimulation. Upon activation with ATP for a relatively short
period (2s or less), P2X7 opens a nonselective cation channel
facilitating Na+ and Ca2+ influx and K+ efflux while prolonged
ATP stimulation (4s or above) leads to the formation of a
macropore permeable to molecules of <900 Da. However,
recent reports have shown that ATP activated P2X7 receptors
can open a NMDG+-permeable macropore within milliseconds
and without progressive dilatation (Harkat et al., 2017; Pippel
et al., 2017). Formation of this large molecular weight-permeable
pore has been associated with the release of ATP in the
microenvironment (Pellegatti et al., 2005; Adinolfi et al., 2010).
Extracellular ATP helps to sustain macropore opening and is
likely to drive several physiological and pathological mechanisms
including chronic pain (Sorge et al., 2012), proliferation and
activation of microglia (Bianco et al., 2006; Monif et al., 2009)
and the death of enteric neurons during colitis (Gulbransen et al.,
2012). In healthy tissues, P2X7 is expressed mainly in the central
nervous system (CNS), peripheral nervous system (PNS), and in
immune cells, which supports its emergence as a target for
chronic pain and chronic inflammatory diseases (De Marchi
et al., 2016). P2X7 is also overexpressed in a number of cancer
types, potentially driving tumor development and survival
(Adinolfi et al., 2002; Adinolfi et al., 2009; Adinolfi et al., 2012;
Barden et al., 2014; Amoroso et al., 2015; Barden et al., 2016;
Gilbert et al., 2019).
As a consequence of its ion channel activity, P2X7 is involved
in driving several functions known to be important during tumor
initiation and progression (Di Virgilio et al., 2018a). Yet, analysis
of sequencing repositories from large tumor panels, including
deep sequencing initiatives, does not highlight the preferential
selection of mutation or copy number variation in the P2RX7
gene by tumor cells (Lawrence et al., 2014). This suggests that
other receptor control mechanisms might modulate the critical
role P2X7 plays during cancer progression. Extracellular ATP is
present at low levels in healthy tissues but increases dramatically
in response to tissue damage, inflammation, hypoxia, ischaemiaFrontiers in Pharmacology | www.frontiersin.org 2and in the tumor microenvironment (TME). This increase in
extracellular ATP has been attributed to cell death, cell stress,
vesicular release, activation of pannexin and connexin, and to
ATP-binding cassette (ABC) transporters (Pellegatti et al., 2008;
Eltzschig et al., 2012; Galluzzi et al., 2017). In the TME,
extracel lular ATP is hydrolyzed into AMP by the
ectonucleotidase CD39, AMP is then hydrolyzed into
adenosine by the CD73 ectonucleotidase (Allard et al., 2017).
While extracellular ATP acts as a DAMP to trigger
proinflammatory immune responses, adenosine was found to
be a potent immunosuppressor (Di Virgilio et al., 2018a). In this
context, P2X7 collaboration with purinergic related proteins
such as CD39 and Pannexin 1, was found to play an important
role in the regulation of the antitumor immune response (de
Andrade Mello et al., 2017).
The high extracellular ATP concentration found in the TME is
sufficient to open the P2X7 macropore that could in turn lead to
membrane depolarization and ultimately to cell death. To support
tumor progression, cancer cells need to inhibit P2X7 macropore
activity while retaining other receptor signaling functions. Several
studies have described molecular mechanisms that lead to loss or
attenuation of macropore function (See Table 1). These include
the report of a misfolded form of P2X7 termed nonfunctional
P2X7 (nfP2X7) that is characterized by the exposure of an
extracellular epitope named E200 (Gidley-Baird and Barden,
2002; Barden et al., 2014; Gilbert et al., 2019). In this review we
seek to describe how the interplay between P2X7 functions drive
tumor progression and immune escape. We first present the
topological features, functions and processes activated
downstream of the P2X7 receptor before discussing how the
interplay between these features may explain the paradoxical
role of P2X7 in the tumor and the immune compartment. We
then discuss the expression and role of P2X7 across multiple
cancer types before reviewing the therapeutic approaches taken to
target P2X7 to date.
Topology of the P2X7 Receptor
The human P2RX7 gene is located on chromosome 12 and
encodes 13 exons that translate into a 595 amino acid protein.
The location of P2RX7 (12q24.31) is adjacent to the P2RX4 gene,
which is only 20Mbp downstream in the same reading direction
(Buell et al., 1998a). Both genes are believed to be derived from
successive gene duplications (Dubyak, 2007; Hou and Cao,
2016). Indeed, a recent report suggests that P2X7 was probably
formed in lower vertebrates through the fusion of a P2X4-like
gene with a Zn-coordinating cysteine-based domain (ZCD)
coding exon (Rump et al., 2020). While heteromerisation of
P2X7 and P2X4 in vivo is still controversial, both genes are found
to be widely coexpressed (Guo et al., 2007; Kaczmarek-Hajek
et al., 2012) and colocalize to act in concert in the regulation of
the same physio-pathological functions (Kopp et al., 2019).
Thirteen P2X7 splice variants have been identified to date
(Benzaquen et al., 2019). While the resolution of the structure
of human P2X7 has not yet been achieved, due to its propensity
to aggregate, the partial structure of human P2X3 (Mansoor
et al., 2016), zebra fish P2X4 (Kawate et al., 2009; Hattori andJune 2020 | Volume 11 | Article 793
Lara et al. P2X7 in CancerGouaux, 2012; Kasuya et al., 2017), chicken P2X7 (Kasuya et al.,
2017), panda P2X7 (Karasawa and Kawate, 2016; Karasawa et al.,
2017), and more recently the full-length rat P2X7 (McCarthy
et al., 2019) have been resolved. These have begun to reveal the
molecular mechanism of ATP channel gating and the topology of
the P2X7 trimer at the cell membrane. The P2X7 receptor is
divided into five main structural domains (Figure 1).Frontiers in Pharmacology | www.frontiersin.org 3N-Terminal Cytoplasmic Tail
A short N-terminal cytoplasmic tail of 25 amino acids (aa),
which is anchored in the membrane via the palmitoylation of a
cysteine residue at position 4 to form a cytoplasmic cap involved
in the sensitisation of the channel to its agonist through key
residues such as T15 and Q17 (Yan et al., 2010; McCarthy et al.,
2019; Liang et al., 2019).TABLE 1 | Channel modifications leading to the loss or gain of P2X7 macropore function.
Designation Type of modification Outcome Reference
Modification leading to Loss of P2X7 Macropore function
V76A SNP Partial loss of macropore function (Stokes et al., 2010; Oyanguren-Desez et al., 2011)
R117W SNP Partial loss of channel and macropore function (Roger et al., 2010; Wiley et al., 2011; Jiang et al., 2013)
G150R SNP Loss of macropore function (Stokes et al., 2010)
E186K SNP Loss of channel and macropore function (Roger et al., 2010; Wiley et al., 2011; Jiang et al., 2013)
N187D SNP Possible loss of function (Chong et al., 2010b)
L191P SNP Partial loss of channel and macropore function (Roger et al., 2010; Wiley et al., 2011; Jiang et al., 2013)
R276H SNP Loss of macropore function (Stokes et al., 2010)
R307Q SNP Loss of macropore function (Gu et al., 2004; Gartland et al., 2012; Jorgensen et al.,
2012; Gu et al., 2015)
A348T SNP Mild increase of channel function in human P2X7 and mild
decrease in channel function in rat P2X7
(Cabrini et al., 2005; Bradley et al., 2011)
T357S SNP Partial loss of channel and macropore function (Cabrini et al., 2005; Shemon et al., 2006)
Q460R SNP Partial loss of channel and macropore function (Cabrini et al., 2005; Stokes et al., 2010)
E496A SNP Loss of channel and macropore function (Gu et al., 2001; Boldt et al., 2003; Cabrini et al., 2005;
Roger et al., 2010; Sun et al., 2010; Gidlof et al., 2012;
Wesselius et al., 2012; Jiang et al., 2013)
I568N SNP Loss of channel and pore function due to impaired P2X7
trafficking to the plasma membrane
(Wiley et al., 2003)
P2X7 variant B Splice variant Loss of macropore function (P2X7 variant A and B
coexpression leads to gain of macropore function)
(Cheewatrakoolpong et al., 2005; Adinolfi et al., 2010)
P2X7 variant C Splice variant Assumed to have lost macropore function (Cheewatrakoolpong et al., 2005; Benzaquen et al., 2019)
P2X7 variant D Splice variant Assumed to have lost macropore function (Cheewatrakoolpong et al., 2005; Benzaquen et al., 2019)
P2X7 variant E Splice variant Assumed to have lost macropore function (Cheewatrakoolpong et al., 2005; Benzaquen et al., 2019)
P2X7 variant F Splice variant Assumed to have lost macropore function (Cheewatrakoolpong et al., 2005; Benzaquen et al., 2019)
P2X7 variant G Splice variants Loss of macropore function (Cheewatrakoolpong et al., 2005; Benzaquen et al., 2019)
P2X7 variant H Splice variants Loss of macropore function (Cheewatrakoolpong et al., 2005)
P2X7 variant J Splice variant Loss of macropore function
(P2X7 variant J act as a dominant negative when
coexpressed with P2X7 variant A leading to loss
macropore function)
(Feng et al., 2006)
N187A Impaired N-
glycosylation
Loss of macropore function (Lenertz et al., 2010)
R578Q Impaired N-
glycosylation
Loss of macropore function (Wickert et al., 2013)
R277 or Y298 Proteolytic cleavage Loss of macropore function following MMP-2 cleavage of
P2X7 extracellular domain
(Young et al., 2018)
C-terminal tail Binding partner NMMHC-IIA (Guo et al., 2007; Gu et al., 2009)
TM domains Cholesterol binding Loss of macropore function (Robinson et al., 2014; Karasawa et al., 2017)
C362S and C363S Prevent cholesterol
inhibition rescue
Loss of macropore function (Karasawa et al., 2017)
Modification leading to Gain of P2X7 Macropore function
H155Y SNP Gain of macropore function (Cabrini et al., 2005; Stokes et al., 2010; Oyanguren-Desez
et al., 2011; Jiang et al., 2013)
A166G SNP Gain of macropore function (Jiang et al., 2013)
H270R SNP Gain of macropore function (Stokes et al., 2010)
R125 ADP-ribosylation of
mouse P2X7
Gating of mouse P2X7 macropore (Adriouch et al., 2008)
R206K, R276K,
R277K (mouse)
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Extracellular Domain
The N-terminal cytoplasmic tail is followed by a first
transmembrane domain named TM1 (aa 26 to 46) and a
large extracellular domain of 282 aa (aa 47 to 329), which
contains an inter-subunit ATP binding pocket (Hansen et al.,
1997; Hattori and Gouaux, 2012; Karasawa et al., 2017;
McCarthy et al., 2019). The extracellular domain also
includes 5 disulfide bonds between cysteine residues 119–
168, 129–152, 135–162, 216–226, and 260–269, which play a
critical role in maintaining the conformation of the
extracellular domain. These disulfide bridges are homologous
across the other members of the P2X receptors which suggest
that they form highly conserved protein folds (Hansen et al.,
1997). Several post-translational modifications have been
identified in the P2X7 extracellular domain which can
regulate receptor functions; these include ADP-ribosylation
of R125 on murine P2X7 that is involved in the gating of the
murine P2X7 receptor (Schwarz et al., 2012) and N-linked
glycosylation of 5 asparagine residues (D187, D202, D213,
D241, and D284) with D187 N-linked glycosylation playing a
key role in the regulation of P2X7 signaling through the MAP
kinase pathway (Lenertz et al., 2010).
Second Transmembrane Domain (TM2)
The extracellular region is followed by a second transmembrane
domain named TM2 (aa 330 to 349), which contains several key
pore-lining residues. These include S342, which sits at the
narrowest part of the channel to regulate its gating (Pippel
et al., 2017; McCarthy et al., 2019). Phosphorylation of the
adjacent Y343 also regulates channel gating which further
emphasizes the importance of those two residues during
channel gating (Kim et al., 2001; Liang et al., 2019).Frontiers in Pharmacology | www.frontiersin.org 4C-terminal Cytoplasmic Tail
The second transmembrane domain is flanked by a long C-
terminal cytoplasmic tail of 245 aa (aa 350 to 595), which acts as
a ballast and is involved in the modulation of macropore opening
(Surprenant et al., 1996; Cheewatrakoolpong et al., 2005; Costa-
Junior et al., 2011; McCarthy et al., 2019). The beginning of the
C-terminal tail contains a cysteine rich region that is
palmitoylated on at least five residues (C362, C363, C374,
C377, and S360) and plays an important role in trafficking of
the receptor to the cell membrane and in preventing receptor
desensitization (Gonnord et al., 2009; McCarthy et al., 2019).
These multiple palmitoylated residues act as a hinge allowing
each C-terminal tail to create two zinc binding sites and a
guanosine diphosphate or triphosphate (GDP/GTP) binding
site. From a functional perspective, the C-terminal tail has
been shown to be required for the opening of the macropore
(Surprenant et al., 1996; Adinolfi et al., 2010). Recent reports
have also shown that pore opening requires movement of the
TM2 helix which is directly linked to the globular ballast folded
underneath (Pippel et al., 2017; McCarthy et al., 2019). This
suggests that a significant movement of the ballast is needed to
allow for the macropore to form (See Figures 1 and 2). Given the
presence of GDP/GTP binding sites in the P2X7 C-terminal tail,
it is tempting to hypothesize that such a structural
rearrangement may involve an exchange between GDP and
GTP. This type of mechanism has already been extensively
characterized for GTPase enzymes, which promote the
hydrolysis of GTP to GDP to trigger protein interaction and
signaling cascades (Bos et al., 2007). This switch could either be
mediated by P2X7 itself or through accessory proteins such as
GTPase-activating proteins (GAPs) and guanine nucleotide
exchange factors (GEFs). However, further work is needed to
confirm this hypothesis.A B
FIGURE 1 | Topology of the P2X7 receptor. (A) Five main structural domains are present within each P2X7 monomer (B) Positioning of P2X7 monomer in the
trimer. Rendering were generated from the rat P2X7 structure (PDB file 6U9W) (McCarthy et al., 2019) and positioned together with ATP, palmitoyl groups and GDP
(GTP) molecules in relation to the plasma membrane (PM). Rendering were performed using PyMOL (https://pymol.org/).June 2020 | Volume 11 | Article 793
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FUNCTIONALITY
P2X7 is distinguished from other P2X family members by its
relative insensitivity to its natural agonist ATP (EC50 above 80
−100 µM) (Surprenant et al., 1996). ATP binding to the inter-
subunit pocket leads to a rotation of each subunit around its turret
and a widening of the lower body of the P2X7 trimer. This
conformational rearrangement is associated with the opening of
a lateral fenestration in the lower body of the trimer that in turn
allows influx of Ca2+ and Na+ ions into and the efflux of K+ ions
from the cell (Figures 2A, B) (Karasawa and Kawate, 2016;
McCarthy et al., 2019). Several well characterized small molecule
inhibitors have been reported to inhibit this mechanism through
binding to an allosteric pocket located in between the turret of each
subunit, thereby preventing the closure of the turret necessary for
the opening of the channel (Figures 2A, B) (Karasawa and
Kawate, 2016). Observations made using rat P2X7 suggest that
the C-terminal cytoplasmic tail does not significantly regulate
receptor current facilitation, desensitization, affinity for ATP or
its receptor ion selectivity (McCarthy et al., 2019).
Structural analysis of P2X family members together with
experimental characterization and mathematical modeling have
provided insights into the transition states of the P2X7 receptor
following ATP binding. While occupation of all three ATPFrontiers in Pharmacology | www.frontiersin.org 5binding s i tes on the tr imer leads to a symmetric
conformational rearrangement and to channel gating, the
binding of a single ATP molecule leads to an asymmetric
rearrangement of the trimer leaving the fenestration closed and
decreasing the affinity of the second and third ATP binding sites.
Upon binding of a second ATP molecule, a low conductance is
observed with a further decrease in the affinity of the third ATP
binding site (Yan et al., 2010). These observations explain why
P2X7 is relatively insensitive to ATP compared to other P2X
family members. The functional implication is that P2X7 ion
channel activation is only achieved when the level of ATP is
significantly elevated in the extracellular compartment. Such
conditions can be found in the TME, during inflammatory
responses and in chronic inflammatory diseases. In these
settings, P2X7 mediated calcium signaling was shown to
trigger intracellular signaling and changes in gene expression
that are critical for cancer cell survival and proliferation (Di
Virgilio, 2015; Di Virgilio et al., 2017; Di Virgilio et al., 2018a).
Indeed, overexpression of full length P2X7 was shown to
promote tumor growth (Jelassi et al., 2011; Adinolfi et al.,
2012a), while P2X7 blockade was shown to inhibit neoplastic
growth in several experimental models (Adinolfi et al., 2012a;
Adinolfi et al., 2015a; Amoroso et al., 2015; Amoroso et al., 2016;
Giannuzzo et al., 2016; De Marchi et al., 2019; Zhang
et al., 2019a).A
B
FIGURE 2 | Activation of P2X7 receptor. Structures show the top (A) and side view (B) of the P2X7 trimer in the Apo-closed state (PDB file: 6U9V) and ATP bound
open state (PDB file: 6U9W). Each monomer is represented in a different color (blue, red or yellow). ATP binding to the trimer leads to a rotation of each monomer
around its respective turret leading to the opening of a side fenestration and an ion channel through the plasma membrane (PM). Renderings were generated from
the rat P2X7 structure (McCarthy et al., 2019) using PyMOL (https://pymol.org/).June 2020 | Volume 11 | Article 793
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TRANSMEMBRANE MACROPORE
Evidence for ATP-induced dye uptake was first identified in the
1970s and 80s (Rozengurt and Heppel, 1975; Cockcroft and
Gomperts, 1979; Steinberg et al., 1987) but it was only a decade
later that P2X7, previously known as P2Z, was shown to play a
key role in the formation of a transmembrane dye-permeable
macropore (Surprenant et al., 1996; Virginio et al., 1999). The
formation of a transmembrane pore is not believed to be limited
exclusively to P2X7. Other ion channels including P2X2, P2X4,
TRPV1 and ASICs have also been shown to increase
conductance and allow molecules of <900 Da into the cell
(Khakh and Lester, 1999; Li et al., 2015). However, while
P2X2, P2X4, TRPV1, and ASICs undergo a “channel to pore
dilatation” upon prolonged activation, P2X7 pore opening is
almost instantaneous (within milliseconds) (Li et al., 2015;
Pippel et al., 2017).
While demonstration of the P2X7 macropore has been
described extensively in vitro (Di Virgilio et al., 2018b),
opening of the macropore in vivo remains to be demonstrated.
Opening of the macropore allows the flow of ions across the
membrane leading to rapid membrane depolarization and
ultimately to cell death. In vitro assessment of macropore
opening is typically performed by measuring the increase in
fluorescence associated with the influx of ethidium+ (314 Da),
YO-PRO-12+ (375 Da), Lucifer yellow (444 Da), DAPI (277 Da)
or the current associated with N-methyl-D-glucamine+
(NMDG+, 195 Da) influx (Di Virgilio et al., 2019). Given the
significant risk that an open macropore may have on cell
viability, the low sensitivity of P2X7 for ATP provides a first
mechanism of protection for cells. Furthermore, P2X7
macropore opening has been shown to be reversible upon the
removal of ATP within 10 to 15 min from initiation of
stimulation in a mouse macrophage cell line, however
reversibility may be cell type specific (Di Virgilio et al., 1988;
Di Virgilio et al., 2018b). This reversible closure of the macropore
can potentially provide a second mechanism to protect cells from
P2X7-mediated cell death. Although the advantages of gated
opening of the P2X7 pore are not well understood, such transient
mechanisms could allow small molecules, such as peptides and
micro-RNA, to enter or leave the cell (Di Virgilio et al., 1988) as
observed for connexins and pannexins at cell to cell junctions
(Esseltine and Laird, 2016). The demonstration that P2X7 is
permeable to the large natural cation spermidine, a polyamine
molecule involved in cell survival, supports this hypothesis
(Harkat et al., 2017). Since opening of a high conductance
transmembrane conduit has inevitable dire consequences on
cell survival, it is likely that under more physiological
conditions, localized opening of the P2X7 macropore occurs
that will perturb cytoplasmic ion homeostasis at discrete sites
only (Franceschini et al., 2015).
The mechanism(s) leading to macropore opening have been
the subject of much controversy. Several hypotheses have been
proposed to support P2X7 dilatation in response to sustained
agonist stimulation and the involvement of associated proteinsTABLE 2 | Studies confirming the presence of P2X7.
Cancer type Studies confirming the presence of P2X7
Prostate (Slater et al., 2004a; Slater et al., 2005; Maianski et al., 2007;
Adinolfi et al., 2009; Barden et al., 2009; Ravenna et al., 2009;
Adinolfi et al., 2010; Barden et al., 2014; Ghalali et al., 2014;
Qiu et al., 2014; Solini et al., 2015; Barden et al., 2016; Gilbert
et al., 2019)
Lung (Barden et al., 2009; Takai et al., 2012; Jelassi et al., 2013;
Barden et al., 2014; Takai et al., 2014; Schmid et al., 2015;
Gilbert et al., 2019)
Kidney (Liu et al., 2015; Gilbert et al., 2019)
Colorectal (Coutinho-Silva et al., 2005; Barden et al., 2009; Li et al.,
2009; Kunzli et al., 2011; Bian et al., 2013; Barden et al.,
2014; Barden et al., 2016; Qian et al., 2017; Gilbert et al.,
2019; Zhang et al., 2019)
Gastric (Barden et al., 2009; Barden et al., 2014; Calik et al., 2020)
Breast (Slater et al., 2004b; Barden et al., 2009; Li et al., 2009; Tafani
et al., 2010; Jelassi et al., 2011; Huang et al., 2013; Jelassi
et al., 2013; Barden et al., 2014; Chadet et al., 2014; Zheng
et al., 2014; Tan et al., 2015; Draganov et al., 2015; Xia et al.,
2015; Barden et al., 2016; Park et al., 2016; Gilbert et al.,





(Greig et al., 2003; Slater and Barden, 2005; Barden et al.,
2016; Yang et al., 2016; Gilbert et al., 2017)
Melanoma (Slater et al., 2003; White et al., 2005; Shankavaram et al.,
2009; Reinhold et al., 2012; Barden et al., 2014; Roger et al.,
2015; Gilbert et al., 2019)
Leukemia and
lymphoma
(Peng et al., 1999; Gu et al., 2000; Adinolfi et al., 2002; Wiley
et al., 2002; Barden et al., 2003; Zhang et al., 2003; Zhang
et al., 2004; Yoon et al., 2006; Barden et al., 2009;
Constantinescu et al., 2010; Chong et al., 2010b; Chong et al.,
2010b; Wang et al., 2011; Barden et al., 2014; Chen et al.,
2014; Ledderose et al., 2016; Salaro et al., 2016; Salvestrini
et al., 2017)
Neuroblastoma (Kaiho et al., 1998; Schrier et al., 2002; Raffaghello et al.,
2006; Sun, 2010; Gutierrez-Martin et al., 2011; Bianchi et al.,
2014; Amoroso et al., 2015; Gomez-Villafuertes et al., 2015;
Wilkaniec et al., 2017; Ulrich et al., 2018; Gilbert et al., 2019)
Glioma (Wei et al., 2008; Tamajusuku et al., 2010; Ryu et al., 2011;
Tafani et al., 2011; Gehring et al., 2012; Fang et al., 2013;
Barden et al., 2014; Gehring et al., 2015; McLarnon, 2017; Ji
et al., 2018; Bergamin et al., 2019; Kan et al., 2019)




(Feng et al., 2006; Feng et al., 2006; Li et al., 2006; Li et al.,
2007; Barden et al., 2009; Barden et al., 2014)
Bladder (Barden et al., 2009; Barden et al., 2014; Hu et al., 2016;
Gilbert et al., 2019)
Papillary
Thyroid
(Ruggeri et al., 2002; Solini et al., 2008; Barden et al., 2009; Li
et al., 2009; Dardano et al., 2009; Gu et al., 2010; Barden
et al., 2014; Kwon et al., 2014)
Pancreatic (Kunzli et al., 2007; Mistafa and Stenius, 2009; Barden et al.,
2014; Giannuzzo et al., 2015; Giannuzzo et al., 2016; Choi






(Gartland et al., 2001; Alqallaf et al., 2009; Barden et al., 2009;
Liu and Chen, 2010; Adinolfi et al., 2012b; Barden et al., 2014;
Giuliani et al., 2014; Zhang et al., 2019a)
Head and neck (Barden et al., 2009; Barden et al., 2014; Bae et al., 2017)
Testicular (Barden et al., 2009; Barden et al., 2014)
Esophageal (Barden et al., 2009; Barden et al., 2014; Santos et al., 2017)
Trophoblastic (Barden et al., 2009; Barden et al., 2014)
Mesothelioma (Barden et al., 2009; Barden et al., 2014; Amoroso et al., 2016)June 2020 | Volume 11 | Article 793
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Virgilio et al., 2018b)). However, recent analysis of human and
rat P2X7 electrophysiological activity in response to agonist
shows that the macropore function is intrinsic to P2X7 and
does not involve progressive pore dilatation (Harkat et al., 2017;
Pippel et al., 2017). Extracellular ATP is present at
concentrations in the low nanomolar range in healthy tissue
but can increase dramatically upon tissue damage, inflammation
or during tumor development to the tens to hundreds of
micromolar range and reach the high activation threshold of
0.3 to 0.5mM for P2X7 (Di Virgilio, 2015; Morciano et al., 2017;
Di Virgilio et al., 2018b). We demonstrated that antibodies raised
against the E200 epitope of P2X7 bind specifically to cancer cell
lines that are devoid of macropore function but that retain P2X7
ion channel function (Barden et al., 2003; Gilbert et al., 2019). In
these cell lines, overexpressed wild type P2X7 rescues macropore
function but is not detected by antibodies that target E200
supporting the specific exposure of E200 epitope by nfP2X7
(Gilbert et al., 2019). E200 specific antibodies were used to show
that nfP2X7 is present intracellularly and can be released to the
plasma membrane upon stimulation with KM11060, a small
molecule corrector that increases the secretion rate of misfolded
proteins to the membrane as shown previously for the Cystic
Fibrosis Transmembrane Receptor (CFTR) mutants (Robert
et al., 2008). nfP2X7 was also shown to be necessary for cell
survival (Gilbert et al., 2019). Hence, these data suggest that to
sustain growth without compromising survival, cancer cells
expressing high levels of P2X7 have developed a mechanism to
inhibit macropore function while retaining ion channel
functionality (Gilbert et al., 2019).
Although mutations of P2X7, such as E496A, have been
shown to abrogate the macropore (Gu et al., 2001; Ghiringhelli
et al., 2009), we and others have demonstrated that P2X7 is
expressed at the cell membrane in the absence of mutations such
as E496A. This suggests that additional mechanisms are involved
in protecting cancer cells (Gilbert et al., 2019). Indeed, several
other mechanisms have been shown to modulate P2X7
macropore activity. These include splice variants (Benzaquen
et al., 2019), N-glycosylation (Lenertz et al., 2010), ADP-
ribosylation (Adriouch et al., 2008), proteolytic cleavage
(Young et al., 2018), and interactions with binding partners or
other P2X family members (Guo et al., 2007; Gu et al., 2009).
They also include interactions with cholesterol in the membrane
(Robinson et al., 2014; Karasawa et al., 2017), that may attenuate
or abrogate P2X7 macropore formation (summarized in Table
1). One or more of these mechanisms has the potential to protect
ce l l s that possess P2X7 receptors in a high ATP
microenvironment over a sustained time period.P2X7 AS A SCAVENGER DRIVING
PHAGOCYTOSIS
Further to its ability to open an ion channel and macropore,
P2X7 has also been shown to act as a scavenger receptor
promoting phagocytosis of nonopsonised targets such as
apoptotic cells, latex beads and live or dead bacteriaFrontiers in Pharmacology | www.frontiersin.org 7(Staphylococcus aureus and Escherichia coli) under serum free
conditions (Gu B. et al., 2010; Gu et al., 2011; Gu et al., 2012).
Binding of P2X7 to the nonmuscle myosin heavy chain
(NMMHC-IIA) was shown to be required for the engulfment
of particles (Gu B. et al., 2010; Gu et al., 2011). This function is
inversely correlated with P2X7 macropore opening, which
requires NMMHC-IIA dissociation from P2X7 upon ATP
stimulation (Gu et al., 2009; Gu B. et al., 2010; Gu et al., 2011).
P2X7 mediated phagocytosis was first demonstrated in
monocytes and macrophages before being extended to
microglia cells in the CNS where it plays a critical role in the
clearance of nonopsonised particles and debris involved in
neuro-inflammation (Wiley et al., 2011; Gu and Wiley, 2018;
Janks et al., 2018). The ability of the P2X7-NMMHC-IIA
complex to act as a scavenger suggests another P2X7-mediated
role for macrophages infiltrated in the TME where P2X7 would
recognize and promote the phagocytosis of apoptotic cells and
potentially support the presentation of associated antigen to
immune effector cells. Indeed, during inflammation and in the
TME, the extracellular ATP concentration is significantly higher
than in healthy tissues (Di Virgilio et al., 2018b). Under these
conditions, P2X7 (as well as P2X4) stimulation potentiates
phagocytosis by inflammatory macrophages (Zumerle
et al., 2019).DOWNSTREAM EFFECT OF P2X7
ACTIVATION
Several signaling pathways are activated downstream of P2X7
including hypoxia and proinflammatory pathways via hypoxia-
inducible factor 1a (HIF-1a), nitric oxide synthase (NOS2),
cyclooxygenase 2 (COX2) and acute phase protein pentraxin-3
(PTX3) (Tafani et al., 2010). Downstream effects of P2X7
activation also include survival and proliferation pathways
such as the NF-kB (Tafani et al., 2010; Liu et al., 2011),
NFATc1 (Adinolfi et al., 2009), Phosphoinositide 3-kinases
(PI3Ks) (Bian et al., 2013; Amoroso et al., 2015), mitogen-
activated kinases (MAPK) (Bradford and Soltoff, 2002;
Amstrup and Novak, 2003), phospholipase A2, C and D
(Humphreys and Dubyak, 1996; Coutinho-Silva et al., 2003;
Andrei et al., 2004) acid sphingomyelinase (Bianco et al., 2009)
and myc oncogene (Amoroso et al., 2015).
The regulation of downstream signaling pathways by P2X7 is
defined at three levels. First, the concentration and duration of
agonist exposure. While acute exposure to relatively high
amounts of ATP has been shown to activate PI3K/AKT and
AMPK-PRAS-40-mTOR signaling pathways to trigger tumor
cell death (Bian et al., 2013), lower and chronic activation has
been shown to activate the NOD-like receptor containing a pyrin
(NLRP3) inflammasome pathway. Second, regulation may
involve the interaction of P2X7 with other membrane proteins,
such as other P2X family members or Pannexin 1. Third,
interaction with scaffolding proteins associated with the
cytoskeleton such as NMMHC-IIA (Gu et al., 2009). Indeed,
the P2X7 receptor signaling complex has been shown to regulate
the macropore and interact with the actin cytoskeletonJune 2020 | Volume 11 | Article 793
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invo lved in seve ra l mechan i sms tha t a re key to
cancer progression.
Cell Death
The early discovery of the P2X7 macropore drove interest in
P2X7 as a receptor capable of mediating cell death through
disruption of intracellular homeostasis and cytolysis leading to
necrosis (Zanovello et al., 1990; Surprenant et al., 1996).
However, many reports have highlighted cell death
mechanisms associated with P2X7 activation that are typical of
an apoptotic pathway. These include membrane depolarization,
redistribution of phosphatidylserine (PS) to the outer membrane,
caspase 3, 8 and 9 activation and membrane blebbing (Zanovello
et al., 1990; Ferrari et al., 1997a; Humphreys et al., 2000;
Mackenzie et al., 2005). Interestingly, the recent resolution of
the rat P2X7 structure has highlighted the presence of a putative
phospholipid in a perpendicular position to the transmembrane
helices in the middle of the plasma membrane that led McCarthy
and colleagues to suggest that P2X7 might possess an intrinsic
flippase-like function driving PS redistribution to the outer
membrane (McCarthy et al., 2019).
Proliferation
The notion that the P2X7 receptor, together with mediating
cytotoxic activity, also exerts a proliferative drive dates back to
1999, when in a pivotal paper from Baricordi and colleagues, it
was demonstrated that transfection with the receptor conferred a
proliferative advantage to leukaemic cell lines growing in the
absence of serum (Baricordi et al., 1999). In the following years,
the trophic activity of P2X7 was associated with an increase in
mitochondrial function leading to an augmented production of
intracellular ATP (Adinolfi et al., 2005) and, in general, to
increased levels of calcium inside cellular stores (Adinolfi
et al., 2009).
P2X7 calcium channel activity plays a central role in driving
proliferation and is shared by the human splice variant P2X7B
that retains ion channel activity while losing the ability to form a
macropore (Adinolfi et al., 2010). When transfected in the
osteosarcoma cell line Te85, P2X7B causes an increase in
proliferation that is even greater than that attributable to
transfection of P2X7A (Giuliani et al., 2014). Several calcium-
related intracellular pathways involved in cell proliferation were
shown to be activated by the P2X7 receptor. These include the
JNK/MAPK, PI3K/AKT/myc and HIF1a-VEGF pathways
(Adinolfi et al., 2012b; Adinolfi et al., 2015b; Di Virgilio et al.,
2016; Di Virgilio and Adinolfi, 2017; Orioli et al., 2017). Among
these, the nuclear factor of activated T cells (NFAT) pathway is
one of the best characterized. NFAT is a calcium-calcineurin
activated nuclear factor involved in the proliferation of several
cell types including T lymphocytes where P2X7-dependent
activation of NFAT was shown to facilitate clonal expansion
and IL-2 secretion thus positively influencing lymphocytic
growth (Yu et al., 2010). NFATc1 mediated pathway was also
responsible for increased proliferation of HEK-293 (Adinolfi
et al., 2009; Adinolfi et al., 2010) and Te85 cells transfected
with both P2X7A and B isoforms (Giuliani et al., 2014) and wasFrontiers in Pharmacology | www.frontiersin.org 8found to be upregulated in xenografts overexpressing the
receptor (Adinolfi et al., 2012a).
Association between P2X7, proliferation and survival has
been demonstrated in several primary cell types including
osteoblasts (Grol et al., 2013; Agrawal et al., 2017; Yang et al.,
2019), microglia (Monif et al., 2009), and CD8+ memory T cells
(Borges da Silva et al., 2018) where it supports physiological
functions such as inflammatory responses and osteogenesis.
However, increased P2X7 activity was also linked with
increased proliferation and survival in many cancer cell types
including pancreatic cancer (Giannuzzo et al., 2016), leukemia
(Salaro et al., 2016) and glioma (Ji et al., 2018). Indeed, reports
showing enhanced P2X7 expression in tumor tissues compared
with normal tissue across many cancer types suggest a role for
P2X7 during tumorigenesis (See section: The function and
expression of P2X7 across cancer types below). Following the
demonstration of the growth-promoting activity of P2X7 in
vitro, it was also shown in several studies that P2X7 can
influence in vivo tumor growth and that consequently, down-
modulation of the receptor by silencing or pharmacological
intervention can reduce tumor burden in preclinical models
(Di Virgilio et al., 2018a). Adinolfi and colleagues first
demonstrated the growth-promoting activity of P2X7 in four
different tumor models in mice including HEK-293 cells and
ACN neuroblastoma derived xenografts and syngeneic colon
carcinoma and melanoma models (Adinolfi et al., 2012a). Several
studies have confirmed these data and extended them,
demonstrating that P2X7 blockade leads to a general reduction
of tumor burden in neuroblastoma (Amoroso et al., 2015; Ulrich
et al., 2018), mesothelioma (Amoroso et al., 2016), melanoma
(Hattori et al., 2012; Adinolfi et al., 2015a), glioma (Ji et al.,
2018), osteosarcoma (Zhang et al., 2019a) and myeloid leukemia
(De Marchi et al., 2019a).
Autophagy
Autophagy is an important mechanism that maintains cell
homeostasis by eliminating damaged cellular components and
recycling them via metabolic pathways. By doing so, autophagy
safeguards energy production under cellular stress such as
starvation (White et al., 2015). Depending on the time of
activation, autophagy can either help to prevent cancer or exert
a tumor-promoting action (Mulcahy Levy and Thorburn, 2020).
While data supporting P2X7 involvement in autophagy and
cancer progression are limited, the receptor is known to act on
several pathways related to autophagy including the pathway
leading to autophagosome formation (Orioli et al., 2017). Indeed,
P2X7 was shown to activate autophagosome-lysosome fusion by
upregulating Beclin1 (Sun et al., 2015; Mawatwal et al., 2017) and
LC3-II (Young et al., 2015; Fabbrizio et al., 2017; Mawatwal et al.,
2017). In dystrophic myoblasts, P2X7-dependent activation of
autophagy correlated with the ability to form the macropore but
not calcium influx-induced signaling (Young et al., 2015). The
first demonstrations of P2X7-mediated trophic activity were
obtained by growing cells under serum starvation where
autophagy is typically induced (Baricordi et al., 1999; Adinolfi
et al., 2005). Cancer cells cultured under these conditions were
found to upregulate P2X7 expression suggesting that autophagyJune 2020 | Volume 11 | Article 793
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(Gomez-Villafuertes et al., 2015).
Chemotherapy-induced autophagy can be central in the
modulation of the anticancer immune response (Kang et al.,
2020). In particular, autophagy is a key driver in immunogenic
cell death (ICD), a form of cancer cell death, which can elicit a
potent immune response mediated by dendritic cells (DCs) and
CD8+ T lymphocytes that can eradicate residual tumor cells and
prevents metastasis formation following a first therapeutic
intervention (Galluzzi et al., 2017). Several classes of
chemotherapeutics such as anthracyclines and oxaliplatin, are
known to cause the induction of ICD (Galluzzi et al., 2017).
Before ICD takes place, premortem autophagy is required for the
release of ATP in the TME where ATP attracts antigen-
presenting cells via P2Y2 receptors (Michaud et al., 2011; Ma
et al., 2013) and down-regulates Treg infiltration (Pietrocola
et al., 2016), to favor an antitumor immune response. Although a
clear correlation between P2X7 activation and ICD in the TME is
not available, it was recently demonstrated that P2X7 expression
modulates ATP levels in the TME affecting CD73 and CD39
ectonucleotidase and reducing Treg levels and fitness (De Marchi
et al., 2019). P2X7 systemic blockade activated an ICD–like
mechanism in cancer cells leading to tumor growth reduction
and activation of antitumor responses while reducing the tumor-
promoting inflammatory cytokine IL-1b (DeMarchi et al., 2019).
Role of P2X7 in the Immune Response
Analysis of data from P2X7 small molecule inhibitors and
genetic knock out of P2RX7 has demonstrated the key role
played by P2X7 in inflammation and immunity (Di Virgilio
et al., 2017; Adinolfi et al., 2018; Adinolfi et al., 2019) and, as a
consequence, in chronic inflammatory diseases such as
Duchenne muscular dystrophy (Ferrari et al., 1994; Sinadinos
et al., 2015), rheumatoid arthritis (Stock et al., 2012) and
inflammatory bowel disease (Arulkumaran et al., 2011; Eser
et al., 2015). In the TME, the permanent release of DAMPs
including ATP, high mobility group box 1 (HMGB1) and
calreticulin (CRT) drives chronic inflammatory settings that
are supplemented by immunosuppressive signals leading to a
dampening of immune effector cell responses (Galluzzi et al.,
2017). By responding to ATP proinflammatory signals, P2X7
counterbalances the potent immunosuppressive signaling driven
by the ATP degradation product, adenosine (Li et al., 2019). In
the following section, we describe the role of P2X7 in
inflammation and immunity and use this as a foundation to
define the role of P2X7 in the TME.
ATP, released through pannexin-1 hemichannels leads to
activation of P2X7 as well as other P2 receptors including
P2X1, P2X4, P2X5 and P2Y6 and is associated with the
activation of T-cells (Wang et al., 2004; Overes et al., 2008;
Schenk et al., 2008; Tsukimoto et al., 2009; Woehrle et al., 2010).
However, the role of P2X7 in response to extracellular ATP
appears to be central to the proinflammatory response including
the stimulation of CD4+ and CD8+ effector T cells (Aswad et al.,
2005; Schenk et al., 2008), stimulation of natural killer T cells
(Beldi et al., 2008), inhibition of differentiation in type 1Frontiers in Pharmacology | www.frontiersin.org 9regulatory cells, promotion of Treg cell death (Aswad et al.,
2005; Schenk et al., 2011; Figliuolo et al., 2017) and the
differentiation of inflammatory Th17 lymphocytes (Atarashi
et al., 2008; Pandolfi et al., 2016). P2X7 was also found to
collaborate with P2Y2 to promote the chemotaxis of myeloid
cells including macrophages, neutrophils and the recruitment
and activation of DCs (Idzko et al., 2002; Pelegrin et al., 2008;
Savio et al., 2017). P2X7 activation also promotes the
immunosuppressive role of myeloid-derived suppressor cells
(MDSCs) infiltrated in the TME by stimulating the release of
reactive oxygen species (ROS), arginase 1 (ARG1) and
transforming growth factor-b1 (TGF-b1) (Bianchi et al., 2014).
At the molecular level, P2X7 plays a central role in the
assembly and maturation of the NLRP3 inflammasome leading
to the activation of caspase 1 followed by the cleavage of pro-
interleukin 1 beta (pro-IL-1b) into mature IL-1b before IL-1b
is released by macrophages and other immune cells (Ferrari
et al., 1997b). Direct interaction of P2X7 with the components
of the inflammasome including the apoptosis-associated speck-
like protein containing a caspase recruitment domain (ASC)
and the NOD-like receptor family (NLR) has been shown in
neurons, astrocytes and microglial cells (Silverman et al., 2009;
Minkiewicz et al., 2013; Franceschini et al., 2015). However,
following opening of the P2X7 ion channel in response to the
binding of ATP, it is the depletion of cytoplasmic K+ that is the
main driver leading to inflammasome activation (Sanz and Di
Virgilio, 2000; Munoz-Planillo et al., 2013). While other
channels also mediate K+ efflux in response to ATP (Di et al.,
2018), P2X7 activated K+ efflux together with Ca2+ influx
remain central to inflammasome activation and the secretion
of cytokines and chemokines. Among these, IL-1b is a key
proinflammatory cytokine secreted in response to P2X7
activation of the inflammasome (Perregaux and Gabel, 1998;
Perregaux et al., 2000; Solle et al., 2001). Other cytokines and
chemokines are also secreted by a variety of cell types. These
include IL-6 (Solini et al., 1999; Kurashima et al., 2012; Shieh
et al., 2014), IL-8 (Wei et al., 2008), IL-18 (Perregaux et al.,
2000), tumor necrosis factor alpha (TNFa) (Ferrari et al., 2000;
Shieh et al., 2014), CC-chemokine ligand 2 (CCL2 also named
MCP-1) (Panenka et al., 2001; Kurashima et al., 2012; Shieh
et al., 2014), CCL3 (Kataoka et al., 2009), CCL7 (Kurashima
et al., 2012), CXCL2 (Shiratori et al., 2010; Kurashima et al.,
2012), and prostaglandin E2 (PGE2) (Panupinthu et al., 2008;
Barbera-Cremades et al., 2012). P2X7 also triggers activation
and shedding of matrix metalloproteases (MMPs) from
peripheral-blood mononuclear cells (PBMCs) (Gu et al.,
1998; Gu and Wiley, 2006; Young et al., 2018). It also has
been suggested that P2X7 plays a role in the resolution of
inflammation through secretion of the anti-inflammatory
cytokines IL-10 and TGFb and proteins such as annexin A1
(Chessell et al., 2005; Bianchi et al., 2014; Moncao-Ribeiro
et al., 2014; de Torre-Minguela et al., 2016). However, other
reports have demonstrated P2X7 mediated inhibition of soluble
HLA-G and IL-10 secretion by monocytes (Rizzo et al., 2009)
and the negative modulation of HLA-G in women affected with
herpes virus 6 A (Pegoraro et al., 2020).June 2020 | Volume 11 | Article 793
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a s soc i a t ed mo l e cu l a r pa t t e rns (PAMPs ) such a s
lipopolysaccharides (LPS) through a potential LPS binding
motif in the P2X7 C-terminal tail (Denlinger et al., 2001). LPS
activation of TLR receptor also stimulates the production of
pro-IL-1b, which is then processed by caspase-1 following P2X7
and NLRP3 inflammasome activation (Walev et al., 1995).
Similarly, TLR2 and 4 were found to cooperate with P2X4
and P2X7 when activated by biglycan, a ubiquitous leucine-
rich repeat proteoglycan found in the extracellular matrix
(Babelova et al., 2009). P2X7 was shown to interact with the
myeloid differentiation primary response 88 (MyD88) to
activate the NF-kB signaling pathway (Liu et al., 2011).
MyD88 mediates NF-kB signaling downstream of the TLR
receptors and might mediate the cooperation between P2X7
and TLR signaling pathways. P2X7 together with CD14 as a
coreceptor was found to support LPS binding and the
internalization of P2X7 (Dagvadorj et al., 2015). Overall, these
studies support a model whereby activation of TLR2 and 4
cooperate with P2X7 to drive chronic inflammatory settings.
While ATP, PAMPs and biglycan were found to be key ligands
of P2X7 and TLR receptors, in the TME, DAMPs such as ATP
and HMGB1, a ligand for TLR4, are also present in significant
concentrations and capable of driving the chronic inflammatory
settings described above (Galluzzi et al., 2017).
Role of the P2X7 in Immunometabolism
Metabolic reprogramming and the maintenance of
mitochondrial fitness are increasingly recognized as key factors
in T lymphocyte differentiation and effector functions (Borges da
Silva et al., 2018; Bailis et al., 2019). Generation of long-lived T
memory cells depends on efficient oxidative phosphorylation and
fatty acid oxidation, while effector T cells are mainly dependent
on glycolysis (Patel and Powell, 2017). Therefore, mitochondria
have a central role in directing T cell functions. The receptors
and pathways mediating the regulation of mitochondrial
metabolism modulation in T cells are still poorly characterized,
however it is increasingly clear that the P2X7 receptor plays an
important role. P2X7 has long been known as a prototypic
cytotoxic receptor (Di Virgilio et al., 1998), but its tonic
activity also supports healthy mitochondrial metabolism,
enhances ATP production via the respiratory chain and
promotes cell growth (Adinolfi et al., 2005; Adinolfi et al.,
2009). The specific role of P2X7 in supporting metabolic
fitness of long-lived T memory cells has now been
demonstrated (Borges da Silva et al., 2018). Stimulation of the
P2X7 receptor via extracellular ATP is crucial to promote
memory CD8+ T cell generation and long-term survival that is
mediated mainly by a trophic effect on mitochondrial
metabolism and the related increase in ATP synthesis. These
data support a previous report from Di Virgilio and coworkers
showing that P2X7 receptor expression has a broad effect on
immunometabolism through modulation of glycolysis (Amoroso
et al., 2012). Indeed, aerobic glycolysis is also impaired in P2X7-
deficient CD8+ T lymphocytes (Borges da Silva et al., 2018).
Thus, the P2X7 receptor may function as a “metabolic sensor”
that links the DAMP extracellular ATP, to the intracellularFrontiers in Pharmacology | www.frontiersin.org 10energy-producing machinery (i.e., oxidative phosphorylation
and glycolysis).
The “metabolic sensor” function of the P2X7 receptor is of
particular relevance at inflammatory and tumor sites since the
extracellular ATP concentration in the inflammatory or tumor
microenvironments (IME and TME, respectively) is several-fold
higher than in the healthy interstitium (Pellegatti et al., 2008; Di
Virgilio et al., 2018a). The impact of such a high extracellular
ATP concentration on the viability of tumor infiltrated
lymphocytes due to opening of the macropore is not known.
While it is possible that loss of viability may take place, the long-
term presence of infiltrated lymphocytes suggests that
modulation of abrogation of macropore function through one
or more of the mechanisms described in Table 1 is likely to take
place in these cells. Although details of the mechanism whereby
P2X7 ‘transduces’ the information carried by high extracellular
ATP is not fully known, key immune functions are significantly
affected by P2X7 activation (Di Virgilio et al., 2017; Di Virgilio
and Adinolfi, 2017). Most importantly, P2X7 is a major stimulus
for Il-1b and IL-18 release, and therefore for the initiation of
inflammation, potentiation of antigen presentation by DCs and
an efficient immune response, including antitumor immune
responses (Mutini et al., 1999; Di Virgilio et al., 2018a).
Converging reports by multiple laboratories have confirmed
the initial observation by Di Virgilio and coworkers of a potent
P2X7-mediated growth-promoting and stimulatory effect on
human T lymphocytes (Baricordi et al., 1996; Schenk et al.,
2008; Yip et al., 2009; Yu et al., 2010; Danquah et al., 2016). P2X7
is upregulated in Treg and T follicular helper cells (Tfh) that are
severely inhibited by its activation (Gavin et al., 2007; Taylor
et al., 2008; Hale et al., 2013). This is hypothesized to have
important implications for host-microbiota interaction in gut-
associated secondary lymphoid organs where ATP released by
bacteria down-modulates the activity of resident Tfh cells, thus
reducing secretion of high affinity IgA and their binding to
commensal bacteria (Di Virgilio et al., 2018c). Grassi and
coworkers have shown that P2X7 deletion affects microbiota
composition and, in consequence, host metabolic homeostasis
(Perruzza et al., 2017; Proietti et al., 2019). This might be
significant in view of the known role of microbiota in the
pathogenesis of several types of cancer and the influence of
microbiota on the response to immune checkpoint inhibitors
(Gopalakrishnan et al., 2018; Zitvogel et al., 2018; Vivarelli
et al., 2019).P2X7 and Purinergic Signaling in
Antitumor Immunity
The function of the P2X7 receptor in the TME is better
understood in the context of the overall mechanisms that
control the extracellular ATP concentration (Adinolfi et al.,
2019). Of importance is the role of CD39 and CD73
ectonucleotidases, that hydrolyze ATP to adenosine (Vijayan
et al., 2017). Adenosine has long been considered one of the main
drivers of immunosuppression (Antonioli et al., 2013). Yet,
recent data demonstrates that the P2X7, CD39, and CD73 axis
also plays a significant role in the modulation of the TMEJune 2020 | Volume 11 | Article 793
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targeting CD39, with beneficial effects on antitumor responses
that cannot be explained merely by the inhibition of adenosine
generation (Li et al., 2019). The use of P2X7 targeted small
molecule inhibitors and P2RX7 genetic knock out in a murine
melanoma model leads to modulation of CD39 and CD73
expression levels on several immune cell populations including
Tregs, CD4+ effector lymphocytes, macrophage and DCs (De
Marchi et al., 2019). P2X7 null mice show a decrease in tumor-
infiltrated CD8+ T cells and an increase in Tregs overexpressing
the fitness markers PD-1, OX40, and CD73. This outcome
correlated with a decrease of extracellular ATP levels. In
contrast, systemic inhibition of P2X7 with the antagonist
A740003 did not affect the number of tumor-infiltrated CD8+
and Treg lymphocytes but increased the number of CD4+
effector T cells. A reduced expression of CD39 and CD73 was
also observed on CD4+ T cells and in DCs highlighting the
importance of the crosstalk between P2X7, CD39, and CD73 in
these cell types (De Marchi et al., 2019). The collaboration
between P2X7 and CD39 was further demonstrated in two
recent studies investigating the antitumoral activity of a CD39
blocking antibody (Li et al., 2019; Yan et al., 2020). Blocking of
CD39 led to reduced tumor burden and metastatic spread in
several murine models. Anti-CD39 antitumoral activity required
the activation of P2X7 on immune cells as P2X7-mediated
activation of the NLRP3 inflammasome led to IL-18 release by
myeloid cells and induction of pyroptosis (Li et al., 2019; Yan
et al., 2020). These data demonstrate that P2X7 collaboration
with CD39 plays a central role in the regulation of anti-
tumor immunity.
Membrane Blebbing
Membrane blebbing consists of plasma membrane sections
protruding and retracting to create protrusions at the cell
surface. Although the mechanism leading to membrane
blebbing is not fully understood, P2X7 is one of the proteins
that have been shown to initiate this mechanism upon sustained
ATP stimulation for several minutes (MacKenzie et al., 2001).
ATP mediated opening of the P2X7 macropore leads to a large
Ca2+ influx that can induce membrane blebbing. Multiple
proteins are involved in this mechanism. These include the
serine/threonine kinase ROCK I (Morelli et al., 2003), heat
shock protein HSP90 that negatively regulates receptor-
mediated blebbing (Adinolfi et al., 2003) and the epithelial
membrane protein 2 (EMP-2) (Wilson et al., 2002). EMP-2
was shown to interact with the P2X7 C-terminal tail suggesting
that P2X7 mediated blebbing requires opening of the macropore
(Wilson et al., 2002). While membrane blebbing is commonly
associated with cellular stress and the initiation of the apoptotic
pathway, P2X7 may also be involved in triggering reversible
membrane blebbing allowing leukocytes to migrate and invade
through extracellular matrices (Qu and Dubyak, 2009). Finally,
P2X7-mediated membrane blebbing has been proposed as an
early step leading to shedding of microvesicles in the
microenvironment (Qu and Dubyak, 2009).Frontiers in Pharmacology | www.frontiersin.org 11Release of Microvesicles
Since the discovery that P2X7 is central to the release of the
proinflammatory cytokine IL-1b by macrophages, there have
been extensive investigations on how this mechanism occurs,
since IL-1b belongs to the leaderless secretory protein group
lacking the secretory signal necessary for conventional protein
secretion through the endoplasmic reticulum route (Dinarello,
2002). These studies have shown that IL-1b secretion is instead
mainly caused by P2X7 induced nonconventional pathways
including microvesicle shedding, exosomes and modified
lysosomes (MacKenzie et al., 2001; Ferrari et al., 2006;
Pizzirani et al., 2007; Qu et al., 2007; Lopez-Castejon and
Brough, 2011; Piccioli and Rubartelli, 2013). Other studies
further showed involvement of P2X7 in microvesicles that
release cytokines by fibroblasts and microglia (Solini et al.,
1999; Bianco et al., 2005), HIV particles by macrophages
(Graziano et al., 2015) and tissue factor by macrophages and
DCs (Baroni et al., 2007; Moore and MacKenzie, 2007).
Release of ROS
During environmental stress such as ionizing radiation, UV, or
heat exposure, increased ROS production mediates oxidative
stress, damages cellular structures and initiates cell death.
However, low levels of ROS can act as signaling molecules. In
phagocytes, ROS are used as bactericides to complete the
phagocytosis process (D’Autreaux and Toledano, 2007; Reczek
and Chandel, 2015). Hence, cells need to control ROS levels
tightly in order to meet their physiological needs, while
preventing cell death (Dupre-Crochet et al., 2013). Production
of ROS is mediated mainly by NADPH oxidases (NOXs), and the
electron transport chain in mitochondria. During tumor
development, oncogenic stimulation, increased metabolic
activity and mitochondrial defects lead to increased ROS
production forcing cancer cells to increase their antioxidant
capacity to prevent cell death (Reczek and Chandel, 2015).
Several reports have shown the induction of ROS production
downstream of P2X7 activation [reviewed in (Guerra et al.,
2007)]. They show that P2X7-mediated Ca2+ influx leads to
activation of kinases that phosphorylate NADPH oxidases
(NOXs) to activate the production of ROS (Moore and
MacKenzie, 2009; Wang and Sluyter, 2013). However, there are
contradictory reports on the nature of the pathway involved in
the phosphorylation of NOXs. In microglial cells, p38 MAPK
and PI3K but not ERK1/2 have been shown to mediate ROS
production (Parvathenani et al., 2003). In macrophages, two
studies have shown activation of ERK1/2 downstream of PKC, c-
Src, Pyk2 but no involvement of PI3K or p38 MAPK (Lenertz
et al., 2009; Martel-Gallegos et al., 2013) while Noguchi et al.
reported activation of the ASK1, p38 MAPK signaling pathway is
required for ROS production (Noguchi et al., 2008). Low levels of
ATP stimulation increase mitochondrial Ca2+ content leading to
hyperpolarization of mitochondrial potential and increased ATP
production (Adinolfi et al., 2005). In line with these data, P2X7
was shown to drive the expression of glycolytic enzymes leading
to increased glycolysis and oxidative phosphorylation thatJune 2020 | Volume 11 | Article 793
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(Amoroso et al., 2012).CONTROL OF P2X7 LOCALIZATION AS A
MEAN TO MODULATE P2X7 FUNCTION
P2X7 has been shown to localize in several cellular
compartments including the plasma membrane, endoplasmic
reticulum (ER), lysosomes, and phagosomes (Kuehnel et al.,
2009; Robinson and Murrell-Lagnado, 2013). In human
monocytes and lymphocytes, P2X7 was found to be localized
mainly intracellularly while differentiation of monocytes into
macrophages led to P2X7 localizing to the plasma membrane
(Hickman et al., 1994; Gu et al., 2000; Gudipaty et al., 2001). In
contrast, in mouse microglia and macrophages, P2X7 localizes
mainly at the plasma membrane (Boumechache et al., 2009). In
cancer cells, Gilbert and colleagues showed that nfP2X7
colocalizes with the ER marker, calreticulin indicating that a
misfolded form of the receptor may be retained intracellularly.
This was further supported by the relocalization of this form to
the plasma membrane upon treatment with small molecule
corrector KM11060 that increases the rate of protein secretion
(Gilbert et al., 2019). Interestingly, this increased membrane
expression was also stimulated by high ATP concentrations (500
µM and above) that suggests that cells may be using ER to plasma
membrane localization as a mean to regulate P2X7 functions
(Gilbert et al., 2019).
Palmitoylation of cysteine residues at the hinge of the C-
terminal tail was shown to be required for P2X7 to localize to
the plasma membrane and associate with lipid rafts (Gonnord
et al., 2009). While several reports have confirmed P2X7
interaction with lipid rafts in multiple cell types (Bannas
et al., 2005; Garcia-Marcos et al., 2006; Barth et al., 2007),
the localization of P2X7 in lipid rafts may not be exclusive.
Garcia-Marcos et al. have identified two P2X7 pools located in
both lipid raft and nonlipid raft membrane compartments
(Garcia-Marcos et al., 2006). They further showed that the
nonlipid raft P2X7 pool can open a nonselective cation
channel while the lipid raft P2X7 pool only is able to
activate phospholipase A2 (PLA2) (Garcia-Marcos et al.,
2006). Hence, the nature of the lipid content in the
membrane surrounding P2X7 receptors can regulate
receptor signaling and ultimately its function. Indeed,
cholesterol was shown to inhibit P2X7 macropore function
(Robinson et al., 2014; Karasawa et al., 2017) while
sphingomyelin and 1-palmitoyl-2-oleoyl-sn-glycero-3-
phospho-(1’-rac-glycerol) (POPG) were shown to enhance
macropore function (Karasawa et al., 2017). Similarly,
phosphatidylinositol 4,5-bisphosphate (PIP2) was shown to
modulate P2X7 ion channel function (Zhao et al., 2007).
Although no direct interaction was found between P2X7 and
PIP2, several residues in the C-terminal tail (R385, K387 and
K395) were shown to be involved in PIP2 regulation. The
I568N polymorphism also located in the P2X7 C-terminal tail
was shown to impair P2X7 trafficking to the membrane (WileyFrontiers in Pharmacology | www.frontiersin.org 12et al., 2003) while the H155Y polymorphism increased P2X7
localization to the plasma membrane (Bradley et al., 2011).
Evidence from several groups points to the existence of
signaling cassettes located in the C-terminal tail of P2X7 which
supports P2X7 trafficking to the plasma membrane (Denlinger
et al., 2003; Wiley et al., 2003; Smart et al., 2003; Chaumont et al.,
2004). Indeed, Lenertz have shown the presence of an ER
retention/retrieval cassette in the P2X7 C-terminal tail near
R576 (Lenertz et al., 2009). This cassette allows P2X7
monomers to be retained in the ER while being assembled into
trimers. P2X7 channels are then addressed to the plasma
membrane through the secretory pathway (Lenertz et al.,
2009). A similar mechanism has already been reported for
other multimeric membrane receptors such as the N-methyl-
D-aspartate (NMDA), glutamate receptor and the g-
aminobutyric acid type B (GABAB) receptor (Michelsen et al.,
2005). The section of P2X7 C-terminal tail overlapping with that
cassette also was found to bind to phospholipids as well as LPS in
a macrophage cell line thereby modulating receptor membrane
localization and its capacity to signal through the MAP Kinase
and NF-kB pathway (Denlinger et al., 2001; Liu et al., 2011).
The Function and Expression of P2X7
Across Cancer Types
The presence of P2X7 has been shown in a large number of
studies using tumor-derived biopsies, cell lines, xenografts and
syngenic murine models across multiple and diverse cancer
types. The majority of these publications, which demonstrate
the presence of P2X7, have not directly assessed functionality of
the P2X7 macropore. Given the high concentration of ATP in
solid tumors, present at levels capable of inducing P2X7 pore
activation (Pellegatti et al., 2008) and thereby death, it is unlikely
that cells expressing fully functional P2X7 could survive in the
TME over extended time periods. Therefore, it is probable that
cells expressing P2X7 within the TME need to express P2X7
predominantly in a form where pore activity is attenuated.
Despite this attenuation of pore function, it is clear from a
number of studies that the P2X7 expressed in these cancer cells
retains significant signaling functionality and the ability to drive
the formation, survival and metastatic potential of tumor cells as
previously reported (Jelassi et al., 2011; Adinolfi et al., 2012a;
Amoroso et al., 2015; De Marchi et al., 2019; Gilbert et al., 2019).
The P2X7 receptor is expressed on a number of cancer types
including, but not limited to prostate, lung, kidney, colorectal,
gastric, breast, cutaneous squamous-cell and basal-cell
carcinomas, melanoma, leukemia, neuroblastoma, glioma,
ovarian, cervical, bladder, papillary thyroid, pancreatic and
bone cancer. This includes nfP2X7 (Barden et al., 2014; Gilbert
et al., 2019). The key data demonstrating the expression and
function of P2X7 on these cancer types is discussed below while
Table 2 provides a list of references per cancer type.
Prostate Cancer
In an immunohistochemistry (IHC) study looking at 116
prostate cancer biopsies using an affinity-purified polyclonal
antibody to the E200 epitope of P2X7 (supplied by Biosceptre),June 2020 | Volume 11 | Article 793
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malignant samples regardless of their stage or the age of the
patient (Slater et al., 2004a). This was confirmed using a mouse
monoclonal antibody (BPM09, supplied by Biosceptre)
(Maianski et al., 2007). In another study, increased expression
of nfP2X7 was observed as prostate disease progressed (Barden
et al., 2016). P2X7 expression by IHC also was compared with the
levels of prostate-specific antigen (PSA) in 174 prostate cancer
biopsies (Slater et al., 2005). Increased nfP2X7 staining
correlated with increased PSA levels indicating that P2X7 may
provide a diagnostic biomarker candidate for early prostate
cancer. These results were consistent with those of a separate
study demonstrating increased P2X7 mRNA and protein
expression in prostate tumor samples compared with normal
tissue (Ravenna et al., 2009). Increased P2X7 expression
correlates with expression of epidermal growth factor receptor
(EGFR) and estrogen receptor (ER)a, which are well known
drivers of cancer cell proliferation, suggesting that P2X7 might
cooperate with these receptors to promote cell proliferation
(Ravenna et al., 2009). These observations support the
proposed role for P2X7 in cancer cell survival and proliferation
(Adinolfi et al., 2009; Adinolfi et al., 2010). Indeed, functional
P2X7 was shown to drive invasion and metastasis of prostate
cancer cell lines stimulated by extracellular ATP (Ghalali et al.,
2014; Qiu et al., 2014).Lung Cancer
In a study analyzing P2X7 mRNA expression in 26 patients
with nonsmall cell lung cancer (NSCLC), compared with 21
patients with chronic obstructive pulmonary disease (COPD)
without signs of malignancy, higher P2X7 expression was
observed in bronchoalveolar lavage derived cells of tumors
with distant metastases (Schmid et al., 2015). P2X7 is also
expressed in human NSCLC cell lines including A549, PC9 and
H292 cells but not in the nonmalignant bronchial epithelial
cells BEAS-2B (Barden et al., 2009; Takai et al., 2012; Jelassi
et al., 2013; Takai et al., 2014). In H292 cells, inhibition or
down-regulation of P2X7 abrogated TGF-b1 induced
migration and actin remodeling. P2X7 is required for TGF-
b1-induced exocytosis of ATP that then acts as a paracrine
factor in lung cancer cell model. Overall, these data suggest a
role for P2X7 in promoting invasion and the development of
aggressive forms of lung cancer.
Kidney Cancer
Clear-cell renal cell carcinoma (ccRCC) is the most common
form of renal cell carcinoma. In a study analyzing 273 ccRCC
patients by IHC, P2X7 expression was correlated with the
clinicopathologic features and cancer-specific survival (CSS)
(Liu et al., 2015). Although intratumoral P2X7 expression was
lower than peritumoral P2X7 expression, those patients with
high intratumoral P2X7 expression had a worse prognosis.
Overall, these data suggest that intratumoral P2X7 is involved
in the progression of ccRCC. In contrast, the significant P2X7
expression found in peritumoral tissues may reflect P2X7
involvement in the TME. Further exploration of the cell typeFrontiers in Pharmacology | www.frontiersin.org 13expressing P2X7 in ccRCC TME is now needed to better
understand the nature of that involvement.
Colorectal and Gastric Cancer
P2X7 protein was identified by IHC with staining distributed
throughout the cell in a small number of normal colorectal
epithelia and colon adenocarcinomas (Li et al., 2009). Qian et al.
demonstrated that high P2X7 expression correlated with tumor
size, lymph nodes metastasis, TNM stage and was also associated
with poor overall survival in a cohort of 116 colon carcinoma
(Qian et al., 2017). These contradicting results suggest that there
may be subtypes of colorectal cancer characterized by their level
of P2X7 expression. Indeed, Zhang et al. analyzed normal tissue
and colorectal cancer samples from 97 patients and found both
P2X7 high and P2X7 low populations with P2X7 high population
having increased metastasis and reduced survival (Zhang et al.,
2019b). Both P2X7 and nfP2X7 were identified in human
colorectal cancer epithelium although the nfP2X7 expression
was much more significant (Barden et al., 2014; Gilbert et al.,
2019). While nfP2X7 was identified in the human HT-29 and
Colo-205 colon cancer cell lines (Barden et al., 2009), other
reports have shown P2X7 expression in human HCT8, Caco-2,
Colo-205, and murine MCA38 colon cancer cell lines and the
latter cell line was found to possess functional P2X7 macropore
(Coutinho-Silva et al., 2005; Kunzli et al., 2011; Bian et al., 2013).
Analysis of P2X7 expression in 156 gastric cancers corelated
P2X7 expression with tumor burden and poor survival
suggesting that P2X7 may be involved in the progression of
gastric cancer (Calik et al., 2020).
Breast Cancer
An IHC study analyzing nfP2X7 expression in 40 breast tumors
of diverse histological subtypes demonstrated that nfP2X7
expression was absent in normal and hyperplastic breast
epithelial samples while in situ or invasive lobular or ductal
carcinoma expressed high levels of nfP2X7 (Slater et al., 2004b).
Tumor cells from invasive carcinomas showed membrane
staining as opposed to intracellular staining in in situ
carcinomas. Therefore, nfP2X7 membrane staining may be
stage-specific and nfP2X7 expression levels may help to
distinguish between different stages of breast cancer. P2X7
mRNA and protein also were upregulated under hypoxic
conditions in the noninvasive breast cancer cell line MCF-7
which has a nonfunctional P2X7 pore (Tafani et al., 2010; Chadet
et al., 2014). In contrast, two independent studies looking at
P2X7 expression showed a reduction of P2X7 staining in breast
cancer versus normal tissue (Li et al., 2009; Huang et al., 2013).
The antibodies used in these studies were raised against the C-
terminal tail of the receptor and are therefore likely to mainly
detect P2X7 variant A. These antibodies are unable to
discriminate between functional P2X7 and nfP2X7. Hence,
while discrepancies exist for the expression of P2X7 variant A
in breast cancer, nfP2X7 appears to be specifically upregulated at
the surface of breast cancer cells. Tan et al. reported higher P2X7
expression levels in the breast cancer tissues when compared
with normal breast tissue (Tan et al., 2015). Furthermore, a
positive correlation was observed between P2X7 expression andJune 2020 | Volume 11 | Article 793
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immunohistochemistry analysis.
Cutaneous Squamous-Cell and Basal-Cell
Carcinomas
P2X7 is highly expressed both in nodular basal cell carcinomas
(BCC) and in infiltrative BCC cells where it was shown to be
present in some tumor cell nuclei (Greig et al., 2003). P2X7
expression was also found in the human squamous cell
carcinoma (SCC) cell line A431, (Greig et al., 2003). nfP2X7
protein also was upregulated in 25 SCC compared to 20
keratoacanthomas (KA) (Slater and Barden, 2005). Using an
affinity purified sheep polyclonal antibody to nfP2X7, systemic
treatment of advanced cat SCC showed decreased lesion size
(Barden et al., 2016). In a more recent study, the presence of
nfP2X7 was shown in BCC and antibodies specific for nfP2X7
rather than fully functional P2X7 were shown to be a safe
treatment for BCC with 65% of patients showing reduced
lesion area, 20% showing stable tumor size and 15% with
increased lesion area (Gilbert et al., 2017). Overall, these data
support the targeting of nfP2X7 in BCC and SCC.
Melanoma
In an IHC study looking at 80 human melanoma biopsies,
nfP2X7 protein was overexpressed in malignant tissues when
compared with nonmalignant samples. P2X7 upregulation was
also observed on keratinocytes of the epidermis surrounding the
tumor (Slater et al., 2003). A study analyzing P2X7 in 14 human
melanoma biopsies confirmed the upregulation of P2X7 in
melanoma with over 75% of samples staining positively (White
et al., 2005). Upregulation of P2X7 in melanoma samples was
confirmed in cell lines at the mRNA level. Indeed, whole genome
microarray screening of the NCI-60 cancer cell line panel has
shown full length P2X7 upregulation as a hallmark of melanoma
cell lines (Shankavaram et al., 2009; Reinhold et al., 2012; Roger
et al., 2015). The human melanoma cell line A375 was found to
express P2X7 variant A and to have a functional large pore
(White et al., 2005).
Leukemia
P2X7 is upregulated in T-cell acute lymphoblastic leukemia and
in murine erythroleukemia (MEL) cells (Constantinescu et al.,
2010; Chen et al., 2014). In MEL cells, P2X7 was also shown to
have a functional macropore (Constantinescu et al., 2010). P2X7
was also upregulated in pediatric leukemias (Chong et al., 2010a)
as well as in human myeloid leukaemic cell lines F-36P and HL-
60 (Yoon et al., 2006). In a separate study, P2X7 mRNA and
protein were upregulated in 8 out of 11 cell lines, 69 out of 87
bone marrow mononuclear cell (BMMC) samples from leukemia
patients and 9 out of 10 myelodysplastic syndrome (MDS)
patients (Zhang et al., 2004). Furthermore, P2X7 also was
significantly upregulated in acute myelogenous leukemia
(AML) and acute lymphoblastic leukemia (ALL) (Zhang et al.,
2004). P2X7 expression was found to be higher in AML subtypes
having poor prognosis. Following standard induction, P2X7 was
upregulated in a group with a low remission rate (Zhang et al.,
2004). Increased P2X7 expression was found in lymphocytesFrontiers in Pharmacology | www.frontiersin.org 14from patients with the evolutive form of B-cell chronic
lymphocytic leukemia (B-CLL) (Adinolfi et al., 2002).
Furthermore, P2X7 expression correlated with the severity of
B-CLL. However, the large molecular weight pore function was
not assessed in this study (Adinolfi et al., 2002). In a separate
study, antibodies targeting P2X7 were shown to bind to the
surface of B-CLL cells. While the analysis of P2X7 membrane
expression by flow cytometry suggests that the B-CLL
populations tested are not fully uniform, data suggest that B-
CLL populations with both functional and nonfunctional
macropore can be identified (Gu et al., 2000). Overall, these
data support a role for P2X7 in the progression of leukemia and
the development of aggressive forms of the disease.
Neuroblastoma
In an IHC study, P2X7 was highly expressed in neuroblastoma
irrespective of the tumor grade. P2X7 was also expressed in several
neuroblastoma cell lines including ACN, GI-CA-N, HTLA-230,
GI-ME-N, LAN-5, LAN-1, SK-N-BE-2, and SH-SY-5Y with cell
surface staining characterized for at least ACN (Raffaghello et al.,
2006). P2X7 stimulation in vitro with ATP did not induce
apoptosis of neuroblastoma cells but instead stimulated their
proliferation via the enhanced secretion of substance P, which
suggests that these cells were nonfunctional for P2X7 macropore
(Raffaghello et al., 2006). In an independent study, P2X7 mRNA
expression was analyzed in 131 patients with neuroblastoma
(Amoroso et al., 2015). High P2X7 expression correlated with
poor prognosis while patients with low P2X7 expression levels had
less aggressive tumors (Amoroso et al., 2015).
Glioma
Both mRNA and protein were detected in human glioma cell
lines U-138MG, U-251MG, and M059J. P2X7 was shown to
mediate cell death in response to ATP in glioma cells (Wei et al.,
2008; Tamajusuku et al., 2010; Gehring et al., 2012; Fang et al.,
2013). While U-138 MG and U-251 MG cells appeared to have a
nonfunctional P2X7 pore, M059J glioma cells were reported as
having functional receptor macropore (Gehring et al., 2012).
P2X7 is also upregulated in mouse GL261 glioma cells (Bergamin
et al., 2019). P2X7 was also upregulated in an in vivo model
where rats received an intra-striatal injection of C6 glioma cells
(Ryu et al., 2011). In these cells, P2X7 promoted chemotaxis in
vitro, which suggests that P2X7 may play a role in the metastasis
process of glioma (Ryu et al., 2011). In a separate study, Gehring
et al. showed that high P2X7 expression was a good prognostic
factor for glioma radiosensitivity and survival probability
(Gehring et al., 2015). P2X7 was highly upregulated at the
mRNA and protein level in tumor tissue as opposed to
peritumoral and adjacent normal tissue (Tafani et al., 2011).
P2X7 upregulation was also observed in cancer stem cells from
GBM cultured under hypoxic conditions. This evidence supports
the potential involvement of P2X7 in cancer stem cells (Tafani
et al., 2011).
Ovarian Cancer
P2X7 expression was analyzed by IHC in nine human ovarian
carcinoma biopsies and compared with ovarian surfaceJune 2020 | Volume 11 | Article 793
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was highly expressed in both healthy tissue and ovarian
carcinoma (Vazquez-Cuevas et al., 2014). P2X7 also was found
to be expressed in the human ovarian cancer cell lines SKOV-3
and CAOV-3 (Vazquez-Cuevas et al., 2014). Both P2X7 and
nfP2X7 were expressed in ovarian cancer tissue (Barden et al.,
2014; Gilbert et al., 2019).
Cervical Cancer
IHC analysis of squamous cell cancer of the cervix showed
increased nfP2X7-specific membranous staining when
compared to normal tissue (Barden et al., 2014). In contrast, Li
et al. have reported a decreased expression of full length P2X7 in
tissues of complex hyperplasia with atypia or endometrial
adenocarcinoma compared to normal endometrium, simple
hyperplasia or complex hyperplasia tissues (Li et al., 2007).
Bladder Cancer
Using Protein Pathway Array (PPA) to investigate the expression
of 285 proteins and phosphoproteins in bladder urothelial cell
carcinoma tissues and adjacent nontumor tissues, Hu et al.
reported that expression of P2X7 was an independent factor,
favorable for overall survival (Hu et al., 2016). Both P2X7 and
nfP2X7 were confirmed to be expressed in bladder cancer tissue
in separate IHC studies (Barden et al., 2014; Gilbert et al., 2019).
Papillary Thyroid Cancer
P2X7 mRNA was upregulated in 37 human papillary thyroid
cancer (PTC) samples when compared with adjacent normal
tissue (Solini et al., 2008). P2X7 protein upregulation was also
confirmed by IHC in all malignant tissues tested including the
classical and follicular forms of the disease (Solini et al., 2008).
Adjacent normal tissue was devoid of P2X7 staining. P2X7
staining was found to be diffuse in the cytoplasm and intense at
the cell surface of malignant thyrocytes (Solini et al., 2008).
P2X7 mRNA and protein was also detected in FB1 and FB2
human thyroid cancer cell lines. In response to ATP, these cells
showed a P2X7 dependent release of IL-6, a cytokine associated
with aggressiveness of PTC (Ruggeri et al., 2002; Solini et al.,
2008). P2X7 upregulation in PTC was confirmed by IHC in two
independent studies (Li et al., 2009; Gu L. et al., 2010). P2X7
upregulation was shown to correlate with tumor growth,
capsular infiltration and lymph node metastases (Gu L. et al.,
2010; Kwon et al., 2014). Additional reports showed nfP2X7
expression in PTC tissue (Barden et al., 2009; Barden et al.,
2014). Overall, these studies support a correlation between
P2X7 and nfP2X7 expression and the development of
aggressive PTC.
Pancreatic Cancer
P2X7 mRNA and protein was shown to be upregulated in
chronic pancreatitis and pancreatic cancer tissue and cell lines
in vitro and in vivo (Kunzli et al., 2007; Giannuzzo et al., 2015;
Giannuzzo et al., 2016). P2X7 large pore functionality was not
assessed in these studies. Other reports demonstrated both P2X7
and nfP2X7 expression in pancreatic cancer tissue (Barden et al.,
2014; Gilbert et al., 2019).Frontiers in Pharmacology | www.frontiersin.org 15Bone Cancer
P2X7 was upregulated in osteosarcoma, Ewing sarcoma,
chondromyxoid fibroma as well as in bone cancer cell lines
such as SaOs-2 and HOS (Gartland et al., 2001; Alqallaf et al.,
2009; Liu and Chen, 2010). SaOs-2 cells have a functional
P2X7 large pore (Alqallaf et al., 2009). Moreover, P2X7
upregulation plays a key role in several malignancies
metastasising to the bone that supports an involvement of
P2X7 in the host tissue during the metastatic process
(reviewed in (Di Virgilio et al., 2009; Adinolfi et al., 2012b;
Adinolfi et al., 2015a). P2X7B splice variant was upregulated in
osteosarcoma and its expression was associated with cell
proliferation (Giuliani et al., 2014).THERAPEUTIC APPROACHES TAKEN TO
TARGET P2X7
Several pharmaceutical organizations have engaged in the
development of both small-molecules and biologics directed
against P2X7 (Mehta et al., 2014; Baudelet et al., 2015;
Jacobson and Muller, 2016) (Table 3). These developments
can be seen in the increasing number of filed patents for P2X7
targeted treatment (Gunosewoyo and Kassiou, 2010; Sluyter
and Stokes, 2011; Park and Kim, 2017; Pevarello et al., 2017).
Early development of small molecule inhibitors targeted the
P2X7 orthosteric site to compete ATP mediated P2X7
activation. However, the lack of specificity of these
inhibitors led to the identification and development of
several classes of inhibitors that bind to the inter-subunit
allosteric pocket preventing ATP induced rotation of each
subunit and closure of the turret (Karasawa and Kawate,
2016). Within this inter-subunit allosteric pocket, several
point mutants including but not limited to F88A, D92A,
F95A, and F103A were identified to play an important role
in the mode of action of these inhibitors (Allsopp et al., 2017;
Allsopp et al., 2018; Bin Dayel et al., 2019). Engagement of this
allosteric pocket allowed progressive development of
antagonists in the low nanomolar range (Table 2) while
providing better selectivity for P2X7 against other P2X
family members (Donnelly-Roberts et al., 2009a; Allsopp
et al., 2017; Allsopp et al., 2018; Bin Dayel et al., 2019).
Initial identification of lead candidates against the inter-
subunit allosteric pocket revealed compounds with good
activity against human P2X7 but inactive against the rat
isoform making pharmacology studies difficult (Michel et al.,
2008a; Michel et al., 2008b; Caseley et al., 2015). However,
docking of these candidates in the inter-subunit allosteric
pocket highlighted the importance of human F95 (L95 in rat
P2X7) in developing pi-stacking interactions with inhibitors
(Caseley et al., 2015; Allsopp et al., 2017; Allsopp et al., 2018).
Several of these small molecules including AZD9056
(AstraZeneca), CE-224,535 (Pfizer), EVT-401 (Evotec), and
GSK1482160 (GlaxoSmithKline plc) have entered clinical
studies to treat rheumatoid arthritis as well as other
inflammatory conditions (Table 2). Although all clinical dataJune 2020 | Volume 11 | Article 793
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Binding site/other targets Development stage Disease se
Nonselective inhibitors
Suramin Small molecule > 300 mM (change in current) Orthosteric site; Binds to multiple
other targets including several P2
receptor subtypes, several growth
factors, human immunodeficiency
virus (HIV) reverse transcriptase,
vasoactive intestinal peptide
receptors and G protein–coupled
receptors.
In the clinic Used as antiparasit
against trypanosom
Tested in the clinic
treatment of autism
foot and mouth dis
Tested as combina
chemotherapy in m
and blood born tum
NF279 (Suramin
analog)
Small molecule 20 µM (Ca2+ influx at 3min)
891 nM (Yo-Pro uptake)
Orthosteric site
High affinity to P2X1
Preclinical N/A
MRS2159 Small molecule 1.7 µM (Ca2+ influx at 3min)
288 nM (Yo-Pro uptake)






100–300 mM (change in
current)





Small molecule 3.2 µM (Ca2+ influx at 3min)
1.2 µM (Yo-Pro uptake)







Small molecule 407 nM (Ca2+ influx at 3min)
200 nM (Yo-Pro uptake)
Orthosteric site Preclinical N/A
KN-62 Small molecule 10 µM (Ca2+ influx at 3min)
214 nM (Yo-Pro uptake)
Inter-subunit allosteric pocket and
central cavity involving D92, F103,
T90, and V312 in human P2X7.






Small molecule < 100 µM (Ca2+ influx at
3min)
1.9 µM (Yo-Pro uptake)
Inter-subunit allosteric pocket and
central cavity involving D92, F103,
and V312 residues.




A438079 Small molecule 123 nM (Ca2+ influx at 3min)
933 nM (Yo-Pro uptake)
Inter-subunit allosteric pocket
involving F88, D92, T94, F95, and
F103 residues.
Preclinical N/A
A740003 Small molecule 44 nM (Ca2+ influx at 3min)
93 nM (Yo-Pro uptake)
Inter-subunit allosteric pocket
involving F88, D92, T94, F95 and
F103, M105 and V312 residues.
Preclinical N/A
A804598 Small molecule 11 nM (Ca2+ influx) Inter-subunit allosteric pocket





TABLE 3 | Continued
settings References
(Honore et al., 2009)
(Michel and Fonfria, 2007; Karasawa
and Kawate, 2016; Allsopp et al.,
2017)
(Stokes et al., 2006; Caseley et al.,
2015; Bin Dayel et al., 2019)
hritis (Keystone et al., 2012; McInnes et al.,
2014)
matory disease (Di Virgilio et al., 2017; Han et al.,
2017)
(Michel et al., 2008a; Karasawa and
Kawate, 2016)




M.G. Kelly, J. Kincaid,
Bicycloheteroaryl compounds as
P2X7 modulators and uses thereof,
US 7297700, 2007.
Evotec Announces the Successful
Completion of the First Phase 1






































Binding site/other targets Development stage Diseas
A839977 Small molecule 20–150 nM (Ca2+ influx and
Yo-Pro uptake)
Not known Preclinical N/A
AZ10606120 Small molecule 10 - 200 nM (Ethudium
uptake and Ca2+ influx)
Inter-subunit allosteric pocket
involving residues 73 to 79, T90,
T94, F103, and V312 residues.
Preclinical N/A
AZ11645373 Small molecule 10–20 nM (change in current
and Yo-Pro uptake)
Inter-subunit allosteric pocket
involving L83, S86, F88, D92, T94,
F95, P96, F108, I310, and V312
residues.
Preclinical N/A





GSK1482160 Small molecule Kd=5.09 ± 0.98 nmol/l,





Phase 1: First Time in Human
Study Evaluating the Safety,
Tolerability, Pharmacokinetics,
Pharmacodynamics and the










of human P2X7 but positive
allosteric modulator of rat
P2X7 at high concentrations.
Inter-subunit allosteric pocket
involving F103 and V312 residues.
Preclinical N/A
CE-224535 (Pfizer) Small molecule 4 nM (Yo-Pro uptake)
1 nM (IL-1b secretion)
noncompetitive, negative allosteric
modulators
Phase 2a: Efficacy and safety
of CE-224,535, an antagonist
of P2X7 receptor, in treatment






EVT-401 (Evotec) Small molecule Not known Not known Phase 1 in healthy volunteers















(Bhattacharya et al., 2013; Karasawa
and Kawate, 2016)
(Lord et al., 2014)
(Lord et al., 2015)
(Lord et al., 2015)
(Swanson et al., 2016)
(Buell et al., 1998b)
(Adriouch et al., 2008)
(Adriouch et al., 2008)
(Adriouch et al., 2008)
(Kurashima et al., 2012)
(Danquah et al., 2016)
(Danquah et al., 2016)
(Danquah et al., 2016)
































Binding site/other targets Development stage D
JNJ47965567 Small molecule 5 nM (Ca2+ influx) Inter-subunit allosteric pocket
involving F88, F103, M105, F108
and V312 residues.
Preclinical N/A
JNJ42253432 Small molecule 20nM (Ca2+ influx) Not known Preclinical N/A
JNJ54232334 Small molecule 0.3 nM against human P2X7,
32 nM against rat P2X7 (Ca2+
influx)
Not known Preclinical N/A
JNJ54140515 Small molecule 79 nM against rat P2X7 (Ca2+
influx)
Not known Preclinical N/A
JNJ54166060 Small molecule 4 nM (Ca2+ influx) Not known
Inhibits CYP3A (IC50 = 2 mM)
Preclinical N/A
Biologics
L4 mAb 5nM (change in current) Not known Preclinical N/A
Hano43 Rat mAb N/A Not known N/A N/A
Hano44 Rat mAb N/A Paratope includes R151 in finger-




N/A Paratope includes R151 in finger-
like structure cysteine-rich region
N/A N/A
1F11 Rat mAb N/A Not known N/A N/A
13A7 nanobody Bivalent
nanobody-Fc
0.5 nM (inhibit CD62L
shedding in mouse cell line)
Bind finger-like structure cysteine-
rich region (same region as







0.1 nM (enhanced CD62L
shedding in mouse cell line)
Bind finger-like structure cysteine-
rich region (same region as





0.2 nM (Ca2+ influx and DAPI
uptake)
Not known Preclinical N/A
BIL010t Polyclonal Anti-
nfP2X7 ointment
N/A E200 peptide in P2X7 extracellular
domain
Investigation of the Safety and






BIL06v Vaccine N/A E200 peptide in P2X7 extracellular
domain
A Phase 1 Study to Evaluate
the Safety, Tolerability,
Immunogenicity and Antitumor
Activity of BIL06v/Alhydrogel in
Patients with Advanced Solid




Lara et al. P2X7 in Cancerare not yet available, no clear benefits to patients have been
observed so far (Jacobson and Muller, 2016; Di Virgilio et al.,
2017). A recent report of an anti-P2X7 bivalent nanobody-Fc
with IC50 in the sub-nanomolar range developed by Ablynx (now
Sanofi) appear to show promising preclinical efficacy in chronic
inflammatory disease models (Danquah et al., 2016). As reports
increasingly highlight the critical role of P2X7 and ATP in tumor
biology and its microenvironment, the rationale for targeting
P2X7 in cancer in single or combination therapies is becoming
increasingly relevant (Di Virgilio et al., 2017; Li et al., 2019).
Indeed, the recent report of the well-tolerated BIL010t, topical
anti-P2X7 treatment of BCC (Biosceptre) revealed promising
patient outcomes with 65% of patients treated showing reduced
lesion area and 20% with stable disease (Gilbert et al., 2017).
Assessment of safety and immunogenicity of an anti P2X7
vaccine (BIL06v – Biosceptre) used in patients with advanced
solid tumors is ongoing in Australia.CONCLUSION
Since the discovery of P2X7 as a cytotoxic receptor, studies have
shown that the role of P2X7 in tumor biology and its
microenvironment is much more complex than initially
thought. Because of the significant involvement of P2X7 in the
diverse mechanisms that drive tumor progression, this receptor
is now believed to be of significant value as a target for the
development of new cancer therapies. Preclinical and clinical
evidence of P2X7-targeted therapeutics demonstrate the
potential for these candidates as innovative cancer therapies.
Furthermore, the interplay between the activities of P2X7 in
tumor cell biology and antitumor immune responses indicates
that P2X7 targeted therapies could also be of significant value
when used in combination therapies. Therefore, additional
studies, to better link the molecular mechanisms associated
with P2X7 activation, signaling and cancer development, are
now needed to drive highly innovative, safe and effective first in
class therapeutics into the clinic.Frontiers in Pharmacology | www.frontiersin.org 19AUTHOR CONTRIBUTIONS
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